Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test) research hub

ABCSG 45: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status

This study looks at a new combination treatment for a specific type of early breast cancer. It compares giving a drug called olaparib with carboplatin before surgery, with a standard chemotherapy. The aim is to see if the new treatment shrinks the cancer more effectively.